Chronic Obstructive Pulmonary Disease (COPD)
This study investigates if inhaled COPD medicines can also protect you from serious heart events, such as heart attacks and heart failure, as well as reducing COPD flare-ups.
Qualification Requirements
- Men and Women
- Ages 40 to 80 years old
- Current or former smoker
- Have one or more cardiovascular risk factors (such as High Blood Pressure, Diabetes, Chronic Kidney Disease, High Cholesterol, or Obesity)
COMPENSATION UP TO: $1,400
Study Details
This clinical research study delves deeper into the potential dual benefits of standard inhaled COPD medications. We are investigating the hypothesis that these treatments, while primarily aimed at improving lung function and reducing COPD flare-ups, may also offer significant protective effects against serious cardiovascular events like heart attacks and heart failure. This is particularly relevant as individuals living with COPD often face an elevated risk of heart-related complications, and understanding how treatments affect both systems is crucial.
The study focuses on evaluating specific inhaled therapies commonly prescribed for managing COPD. Participation is sought from individuals diagnosed with COPD aged 40-80 who are current or former smokers and also have one or more established cardiovascular risk factors, such as hypertension, diabetes, high cholesterol, chronic kidney disease, or obesity. By focusing on this population, the research aims to directly assess the potential cardiovascular protective effects of these medications in those who may be most vulnerable to heart events alongside their respiratory condition.